New therapies for systemic lupus erythematosus — past imperfect, future tense

A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea

(2018) Fengchun Zhang et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study

(2018) Luca Iaccarino et al.   JOURNAL OF AUTOIMMUNITY

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

(2018) Daniel J Wallace et al.   LANCET

Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosus

(2018) Pedro L Carreira et al.   RHEUMATOLOGY

Comprehensive assessment of the association between genes on JAK-STAT pathway (IFIH1, TYK2, IL-10) and systemic lupus erythematosus: a meta-analysis

(2018) Qiong Yin et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

(2018) Ronald F van Vollenhoven et al.   LANCET

OUP accepted manuscript

(2018)   RHEUMATOLOGY

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples

(2017) Venkat Reddy et al.   RHEUMATOLOGY

Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register

(2017) Eoghan M McCarthy et al.   RHEUMATOLOGY

Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years

(2017) R. Aguiar et al.   ARTHRITIS CARE & RESEARCH

Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins

(2017) Venkat Reddy et al.   ARTHRITIS CARE & RESEARCH

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

(2017) Richard Furie et al.   Arthritis & Rheumatology

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study

(2017) William Stohl et al.   Arthritis & Rheumatology

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

(2016) Munther Khamashta et al.   ANNALS OF THE RHEUMATIC DISEASES

Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study

(2016) Julie Ducreux et al.   RHEUMATOLOGY

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction

(2016) Yasuko Furumoto et al.   Arthritis & Rheumatology

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

(2015) J T Merrill et al.   ANNALS OF THE RHEUMATIC DISEASES

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)

(2015) Kenneth C Kalunian et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study

(2015) D A Isenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)

(2014) David Isenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

(2014) Arthur Kavanaugh et al.   ANNALS OF THE RHEUMATIC DISEASES

Why and how should we measure disease activity and damage in lupus?

(2014) Joy Feld et al.   PRESSE MEDICALE

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study

(2013) Eduardo F. Mysler et al.   ARTHRITIS AND RHEUMATISM

B-cell-targeted therapies in systemic lupus erythematosus

(2013) Vera Sau-Fong Chan et al.   Cellular & Molecular Immunology

Atherosclerosis in Systemic Lupus Erythematosus

(2013) George Stojan et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis

(2013) A. L. Rankin et al.   JOURNAL OF IMMUNOLOGY

Brutonˈs tyrosine kinase-an integral protein of B cell development that also has an essential role in the innate immune system

(2013) Gabriela López-Herrera et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Taking a closer look at biologic therapy for SLE

(2013) David A. Isenberg et al.   Nature Reviews Rheumatology

Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial

(2012) Robert Zimmer et al.   ANNALS OF THE RHEUMATIC DISEASES

Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis

(2012) George K Bertsias et al.   ANNALS OF THE RHEUMATIC DISEASES

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid

(2012) Bernard R. Lauwerys et al.   ARTHRITIS AND RHEUMATISM

Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice

(2012) L. P. Kil et al.   BLOOD

The genetics of type I interferon in systemic lupus erythematosus

(2012) Paola G Bronson et al.   CURRENT OPINION IN IMMUNOLOGY

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

(2012) Bevra H. Hahn et al.   ARTHRITIS CARE & RESEARCH

Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

(2012) Jack Hutcheson et al.   ARTHRITIS RESEARCH & THERAPY

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Assessment of a lupus nephritis cohort over a 30-year period

(2011) S. C. Croca et al.   RHEUMATOLOGY

FcγRIIB, FcγRIIIB, and systemic lupus erythematosus

(2010) Heather A. Niederer et al.   Annals of the New York Academy of Sciences

IL-23: A Promising Therapeutic Target for Systemic Lupus Erythematosus

(2010) Rui-Xue Leng et al.   ARCHIVES OF MEDICAL RESEARCH

Molecular mechanism and function of CD40/CD40L engagement in the immune system

(2009) Raul Elgueta et al.   IMMUNOLOGICAL REVIEWS

The role of B cells in lupus pathogenesis

(2009) Emil Nashi et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality

(2009) F Goldblatt et al.   LUPUS

The Spliceosomal Phosphopeptide P140 Controls the Lupus Disease by Interacting with the HSC70 Protein and via a Mechanism Mediated by γδ T Cells

(2009) Nicolas Page et al.   PLoS One

Interferon Alpha-Induced Lupus

(2008) Timothy B. Niewold   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY